Home » Esperance Enrolls Patients for Studies of Membrane-Disrupting Agent
Esperance Enrolls Patients for Studies of Membrane-Disrupting Agent
Drug discovery and development company Esperance Pharmaceuticals announced that it has begun enrollment and dosing of patients in a Phase I study of EP-100 in patients with advanced solid tumors.
Earth Times
Earth Times
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May